A carregar...

Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.

In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were ob...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Van Gerwen, F, Van der Korst, J K, Gribnau, F W
Formato: Artigo
Idioma:Inglês
Publicado em: 1978
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1000198/
https://ncbi.nlm.nih.gov/pubmed/343727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!